Microalbuminuria and cardiorenal risk: old and new evidence in different populations

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Microalbuminuria (MAU) is a recognized marker for cardiovascular (CV) risk and target organ damage.
• MAU is particularly relevant in patients with hypertension, chronic kidney disease (CKD), and diabetes.
• Identifying MAU is crucial for stratifying patients into high or very high global CV risk categories.

Purpose of the Study:

• To highlight the significance of MAU as an integrated marker of CV risk.
• To emphasize the importance of MAU screening in at-risk populations.
• To discuss the potential for intensive treatment to reverse MAU and mitigate CV risk.

Main Methods:

• Diagnosis of MAU is established through 24-hour urine albumin collection or, more practically, the urinary albumin-to-creatinine ratio (UACR) in a morning urine sample.
• Screening for MAU is recommended for individuals at elevated global CV risk.
• Treatment strategies involve intensive management of hypertension, diabetes, and other CV risk factors.

Main Results:

• MAU serves as a specific integrated marker for cardiovascular risk and target organ damage.
• Evidence supports that intensive therapeutic interventions can lead to the normalization of albuminuria levels (normoalbuminuria).
• Comprehensive treatment regimens, including ACE inhibitors or ARBs, antihypertensives, MRAs, new anti-diabetic drugs, and statins, can reduce the risks associated with albuminuria.

Conclusions:

• MAU is a critical indicator for identifying patients with elevated cardiovascular risk.
• Intensive treatment strategies targeting multiple risk factors can effectively manage and potentially reverse MAU.
• Early detection and management of MAU are essential for reducing cardiovascular morbidity and mortality in high-risk patients.